Blog
RSS FeedPosted by Michael Wonder on 20 Feb 2019
Updates for patients and communities
20 February 2019 - After spending the fall listening to patient groups and exploring how other organisations have involved patients ...
Posted by Michael Wonder on 20 Feb 2019
New drug landscape dominated by high cost medicines
19 February 2019 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, ...
Posted by Michael Wonder on 14 Feb 2019
Quebec appeals court orders province to restore full coverage of rheumatoid-arthritis drug Remicade
13 February 2019 - Quebec’s highest court has ordered the provincial government to restore full public coverage of Remicade, an ...
Posted by Michael Wonder on 09 Feb 2019
U.S. PhRMA's fight to prevent lower Canadian drug prices
9 February 2019 - Drug industry turns up heat against Canada's drug price reforms. ...
Posted by Michael Wonder on 07 Feb 2019
Facing crackdown in Canada, drug makers offered billions in price cuts
6 February 2019 - Delayed rules would change countries Canada compares its prices to, dropping U.S. ...
Posted by Michael Wonder on 06 Feb 2019
New opportunity: parallel scientific advice from CADTH and NICE
6 February 2019 - CADTH is pleased to announce a new collaboration with England’s NICE (National Institute for Health and ...
Posted by Michael Wonder on 05 Feb 2019
Relief, but at what cost? The steep price of modern psoriasis medications
5 February 2019 - Biologics offer great relief to most, but hard to get coverage for. ...
Posted by Michael Wonder on 04 Feb 2019
Let’s make 2019 the year Canada finally gets pharmacare
4 February 2019 - Last week, Reuters reported that the Trudeau government is planning to introduce pharmacare in its next ...
Posted by Michael Wonder on 24 Jan 2019
Ottawa’s push for lower drug costs may hurt patients, stunt innovation
24 January 2019 - The federal government’s plan to lower prescription drug prices could impede access and thus limit the ...
Posted by Michael Wonder on 23 Jan 2019
Trudeau spreads the big Pharmacare myth that scores of Canadians can’t afford medicine
23 January 2019 - Across every income group, people pay more for media entertainment than prescription medicine. ...
Posted by Michael Wonder on 23 Jan 2019
The strange world of Canadian drug pricing
22 January 2019 - Imagine yourself in some hip new coffee shop. All you want is your standard cup to ...
Posted by Michael Wonder on 21 Jan 2019
Canadian payer reports a successful switch to biosimilars
21 January 2019 - In 2018, Green Shield Canada launched its pilot Biosimilar Transition Program, through 3 plan sponsors, under which ...
Posted by Michael Wonder on 18 Jan 2019
Canada’s drug pricing regulator brings rare allegation of excessive pricing against Horizon Pharma
17 January 2019 - Canada’s drug-pricing regulator is accusing an Irish pharmaceutical company of charging an excessive price for a ...
Posted by Michael Wonder on 16 Dec 2018
Proposal to harmonise, streamline and transition the Cancer Drug Implementation Advisory Committee to CADTH
14 December 2018 - Providing customised implementation support to decision-makers at all levels of the health system is a key ...
Posted by Michael Wonder on 11 Dec 2018
Glatect added to public drug plan in British Columbia as sole RRMS treatment of its type
11 December 2018 - Pendopharm’s Glatect (glatiramer acetate) — a treatment for patients with relapsing-remitting multiple sclerosis — has been added ...